Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rafarma Pharmaceuticals, a producer of generic antibiotic and specialty pharmaceuticals, has signed a new exclusive contract with JSC F-Synthesis for the production of the oral anti-cancer drug Imatinib.
Subscribe to our email newsletter
The new contract is expected to increase both production and reduce production costs targeting increased sales volume and market share.
Imatinib’s market in Russia for 2012 amounted to slightly less than $200m, according to JSC F-Synthesis.
The tyrosine-kinase inhibitor drug is used in the treatment of multiple cancers, especially Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML).
The targeted therapy works by preventing the growth of cancer cells and eliminating them by apoptosis.